๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Bausch + Lomb Corporation (BLCO)
NYSE: BLCO ยท Real-Time Price ยท USD
19.64
-1.05 (-5.10%)
Nov 20, 2026, 12:35 PM EST - Market open

Bausch + Lomb Earnings Call Transcripts

Fiscal Year 2026

  • Study result

    BL1332 missed the phase II primary endpoint, but both doses favored vehicle across all SPID estimates, with nominal significance for the high dose at six hours. Exploratory results showed more pain-free patients and earlier epithelial recovery; discussions on larger confirmatory studies are planned.

  • Q3 revenue rose 8% on a constant-currency basis, while adjusted EBITDA increased 34% and free cash flow reached $178M. FY 2026 revenue and adjusted EBITDA guidance were raised, with net leverage down to 4.1x.

  • Study result

    A novel dual-action dry eye therapy demonstrated rapid, significant efficacy at day 15 with reduced dosing and strong tolerability, guiding a focused phase III strategy. BL1332, a potent TRPV1 antagonist, showed dramatic pain relief in a phase I-B study, supporting broader development in ocular pain. Both assets are expected to drive substantial long-term growth.

  • Q2 2026 saw 8% revenue growth and 28% adjusted EBITDA growth, with strong performance across all segments and significant margin expansion. Guidance for full-year revenue and EBITDA was raised, supported by robust cash flow and continued deleveraging.

  • Management outlined a strategy focused on operational reliability, innovation, and financial excellence, targeting 5%-7% annual growth and significant margin expansion by 2028. Key innovations like Project Halo and ELIOS are set to drive future growth, with a robust pipeline and disciplined capital allocation supporting long-term market leadership.

  • R&D Day 2026

    Two major contact lens innovations are advancing: Project Halo, a bioactive daily lens with HA for superior comfort, targets a 2028 U.S. launch, while a differentiated myopia control lens for children is set for 2029. Both leverage efficient manufacturing and aim to expand market share.

  • AGM 2026

    The meeting confirmed a quorum and addressed four proposals, including director elections, executive compensation, and auditor appointment, with all voted proposals approved. No shareholder questions were received, and final results will be disclosed in a Form 8-K.

  • Q1 2026 delivered 6% revenue growth and 59% adjusted EBITDA growth, with margin expansion and strong performance across all segments. Guidance for 2026 was raised, reflecting confidence in continued growth, margin improvement, and robust pipeline execution.

  • Status update

    BL 1107, a novel neuroprotective glaucoma therapy, shows significant vision gains and is on track for phase II readout in H2, with phase III to follow. ELIOS, an implant-free excimer laser MIGS, showed durable IOP reduction and medication-free rates, targeting U.S. approval in late 2026. Both assets are expected to drive substantial growth and address major unmet needs.

  • The conference highlighted a robust innovation-driven strategy, with major product launches in consumer, contact lens, pharma, and surgical segments expected through 2029. Margin expansion, double-digit EPS growth, and strong free cash flow are forecast, supported by operational excellence and disciplined capital allocation.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022